Rush University Medical Center, a nationally recognized clinical and academic institution, and the teaching hospital for Rush Medical and Nursing Colleges, located in downtown Chicago, invites applications for a assistant/associate or full professor of medicine with a focus on continued development of the Multiple Myeloma/Plasma Dyscrasia program. The ideal candidate should have at least 1-2 years of experience in an academic setting after Hematology/Oncology fellowship training and has a demonstrated interest in clinical and research interest in myeloma and other plasma cell disorders including amyloidosis. The predominant criteria for all appointments are a major commitment to excellence in clinical care, research, teaching, and, scholarly activity that advances clinical medicine, and institutional service at Rush. The successful candidate will possess professional qualifications that include: Hematology, Medical Oncology or Hematology/Oncology training with board certification/eligibility, MD or MD/PhD (or equivalent), and have experience in clinical and translational research. Candidates should be eligible for a faculty appointment at the Assistant Professor level or above.

Rush has a robust myeloma program that has established regional and national leadership in this field. Rush was the founding organization behind the national syndicated myeloma rounds. Depending upon the credentials of the applicant, there are substantial financial support mechanisms to provide for clinical, administrative, teaching and research activities in the Rush Myeloma & Amyloidosis Program. While a majority of effort will be devoted to clinical activities, protected time will be provided (commensurate with demonstrated research productivity) for research with a focus on expanding clinical and translational research in plasma cell disorders and the amyloidosis program in the first two years. Opportunities for longer-term support are available for enhancing the existing clinical and translational trial program with cooperative group, pharmaceutical sponsors, and investigator-initiated studies. The candidate will also participate in inpatient rounds & teaching medical students, residents, and fellows.

Our new, state-of-the-art Cancer Center facility in Chicago will serve as a hub for services throughout our health system. Our core programs are supported by multi-disciplinary teams from hematology, cell therapy, medical oncology, surgical oncology, radiation oncology, pathology, radiology, research and bioinformatics, clinical operations, and dedicated clinical and support staff, including patient navigators. This structure allows specialists to more easily consult and see patients based on tumor type or molecular and genomic signatures, combining our outstanding multidisciplinary approach with a data infrastructure that supports this patient-centered care. This integration enables us to make a greater commitment to research, dramatically scaling the effectiveness of clinical trials, and enabling translational research that moves bench to bedside, and bedside to bench.